SG11201701669PA - Flavivirus virus like particle - Google Patents

Flavivirus virus like particle

Info

Publication number
SG11201701669PA
SG11201701669PA SG11201701669PA SG11201701669PA SG11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA
Authority
SG
Singapore
Prior art keywords
particle
flavivirus virus
flavivirus
virus
Prior art date
Application number
SG11201701669PA
Inventor
Wataru Akahata
Ryuji Ueno
Original Assignee
Vlp Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlp Therapeutics Llc filed Critical Vlp Therapeutics Llc
Publication of SG11201701669PA publication Critical patent/SG11201701669PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201701669PA 2014-09-11 2015-09-10 Flavivirus virus like particle SG11201701669PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048897P 2014-09-11 2014-09-11
PCT/JP2015/004623 WO2016038895A1 (en) 2014-09-11 2015-09-10 Flavivirus virus like particle

Publications (1)

Publication Number Publication Date
SG11201701669PA true SG11201701669PA (en) 2017-04-27

Family

ID=55453731

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701669PA SG11201701669PA (en) 2014-09-11 2015-09-10 Flavivirus virus like particle

Country Status (13)

Country Link
US (1) US10098943B2 (en)
EP (1) EP3191589A4 (en)
JP (1) JP6942309B2 (en)
KR (1) KR102532832B1 (en)
CN (1) CN106687590B (en)
AR (1) AR101814A1 (en)
AU (1) AU2015313650B2 (en)
CA (1) CA2960102C (en)
MX (1) MX2017003117A (en)
PH (1) PH12017500450A1 (en)
SG (1) SG11201701669PA (en)
TW (1) TWI695842B (en)
WO (1) WO2016038895A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
KR20200051693A (en) * 2017-09-11 2020-05-13 텐겐 바이오메디컬 컴퍼니 Mammalian-specific growth-deficient arbovirus
CN113429479B (en) * 2018-04-04 2023-03-10 中国科学院微生物研究所 High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof
KR101970963B1 (en) * 2018-12-19 2019-04-23 주식회사 엠디헬스케어 DNA aptamer binding specifically to yellow fever virus envelope protein domain III (YFV EDIII) and uses thereof
WO2020242388A1 (en) * 2019-05-28 2020-12-03 Chiang Mai University Mature virus-like particles of flaviviruses

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
DK0710719T3 (en) 1990-01-12 2007-07-09 Amgen Fremont Inc Generation of xenogenic antibodies
WO1993010152A1 (en) 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
AU716466B2 (en) 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
AU2674199A (en) * 1998-02-11 1999-08-30 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
WO1999041383A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Antigen library immunization
JP4896327B2 (en) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド PD-1, B7-4 receptors and uses thereof
CA2448908C (en) 2001-05-30 2008-03-18 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
AU2003269873A1 (en) * 2002-05-13 2003-12-19 The Regents Of The University Of California Chemical modifications to polymer surfaces and the application of polymer grafting to biomaterials
ATE481985T1 (en) 2002-07-03 2010-10-15 Ono Pharmaceutical Co IMMUNOPOTENTATING COMPOSITIONS
US20050031592A1 (en) 2002-11-13 2005-02-10 Doolan Denise L. Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines
CA2527636A1 (en) 2003-05-29 2005-01-06 United States Army Medical Research Institute For Infectious Diseases, A Research Laboratory Owned And Operated By The United States Government A Live attenuated viral vaccines for eastern equine encephalitis virus
JP4506301B2 (en) 2003-09-30 2010-07-21 ブラザー工業株式会社 Ink cartridge and inkjet printer
BRPI0417159A (en) 2003-12-01 2007-03-06 Dow Global Technologies Inc production of recombinant icosahedral virus-like particle in pseudomedities
MXPA06013124A (en) 2004-05-18 2007-05-23 Alphavax Inc Tc-83-derived alphavirus vectors, particles and methods.
AU2007200847B2 (en) * 2004-07-27 2010-06-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
ATE523205T1 (en) 2004-10-14 2011-09-15 Crucell Holland Bv PRIME BOOST VACCINES AGAINST MALARIA
JP4819792B2 (en) 2005-02-16 2011-11-24 国立大学法人東京工業大学 Modified viral capsid proteins and uses thereof
CN104436190A (en) 2005-06-08 2015-03-25 达纳-法伯癌症研究院公司 Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (en) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS
WO2007100098A1 (en) 2006-03-03 2007-09-07 Kyoto University Multimer of extracellular domain of cell surface functional molecule
US20100120092A1 (en) 2006-08-30 2010-05-13 Hepgenics Pty Ltd. Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
JP5627464B2 (en) 2007-11-26 2014-11-19 ノバルティス アーゲー How to generate alphavirus particles
SG171828A1 (en) 2008-11-26 2011-07-28 Us Gov Health & Human Serv Virus like particle compositions and methods of use
CA2774640C (en) 2009-09-18 2019-11-26 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
CN101948850A (en) * 2010-08-13 2011-01-19 中国疾病预防控制中心病毒病预防控制所 Preparation method and application of virus-like particles of dengue viruses
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
JP6147734B2 (en) 2011-06-17 2017-06-14 バハラ バイオテック インターナショナル リミテッド Vaccine composition comprising inactivated chikungunya virus strain
EP2731961A4 (en) 2011-07-12 2015-12-09 Us Government Identification of a west nile virus cd4 t cell epitope and use thereof
CN102321639B (en) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 Preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV) and its application
WO2013063248A1 (en) 2011-10-25 2013-05-02 Florida Gulf Coast University Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
AP2014007864A0 (en) 2012-02-16 2014-08-31 Vlp Therapeutics Llc Virus like particle composition
BR112014024612A2 (en) 2012-04-02 2021-06-08 Univ North Carolina Chapel Hill nucleic acid, polypeptide, glycoprotein and chimeric, dengue virus epitope, chimeric flavivirus-like particle (vlp), chimeric flavivirus, and in vitro methods to identify a neutralizing antibody and to identify an immunogenic composition against a dengue virus
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
CN104812408A (en) * 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 Vaccine compositions for prevention against dengue virus infection
CA2913832C (en) 2013-06-03 2023-07-04 Vlp Therapeutics, Llc A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106795513B (en) 2014-08-08 2021-06-11 Vlp治疗公司 Virus-like particles comprising a modified envelope protein E3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
WO2016109792A2 (en) 2014-12-31 2016-07-07 The Usa, As Represented By The Secretary, Detp. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
CN107849558A (en) 2015-06-12 2018-03-27 国立大学法人三重大学 Human Parainfluenza virus type 2 carrier and vaccine
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
CN108601825B (en) 2015-07-16 2023-06-20 巴拉特生物技术国际有限公司 Vaccine composition
MA42502A (en) 2015-07-21 2018-05-30 Modernatx Inc VACCINES AGAINST INFECTIOUS DISEASE
CN106085974B (en) 2016-06-07 2019-08-09 博奥生物集团有限公司 A kind of zika virus pseudovirion and preparation method thereof

Also Published As

Publication number Publication date
CN106687590B (en) 2021-08-03
CA2960102A1 (en) 2016-03-17
AR101814A1 (en) 2017-01-11
TWI695842B (en) 2020-06-11
EP3191589A1 (en) 2017-07-19
US10098943B2 (en) 2018-10-16
BR112017004770A2 (en) 2017-12-12
BR112017004770A8 (en) 2023-04-11
PH12017500450A1 (en) 2017-07-31
JP2017528139A (en) 2017-09-28
WO2016038895A1 (en) 2016-03-17
MX2017003117A (en) 2017-06-14
EP3191589A4 (en) 2018-05-09
CN106687590A (en) 2017-05-17
AU2015313650A1 (en) 2017-04-13
KR20170055513A (en) 2017-05-19
TW201612190A (en) 2016-04-01
CA2960102C (en) 2023-10-24
JP6942309B2 (en) 2021-09-29
US20160074501A1 (en) 2016-03-17
AU2015313650B2 (en) 2021-07-08
KR102532832B1 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
HK1257480A1 (en) Engineered virus
HK1255670A1 (en) Modified virus-like particles of cmv
GB2535253B (en) Compositions and methods
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
GB201405614D0 (en) Particles
GB201405834D0 (en) Oncolytic virus
SG11201700968PA (en) Formulation comprising particles
GB201406608D0 (en) Virus
PL3152226T3 (en) Modified cyclopentapeptides and uses thereof
GB201506381D0 (en) Embolization particle
SG11201701669PA (en) Flavivirus virus like particle
GB201412841D0 (en) Particles
GB2540240B (en) Catalyst particle
GB201411526D0 (en) Powder
HK1253030A1 (en) Piv5-based amplifying virus-like particles
GB201419572D0 (en) Virus
GB2577405B (en) Particle
SG11201609908VA (en) Virus reduction method
ZA201708393B (en) Large particles
GB201402915D0 (en) Compositions and methods
GB201708709D0 (en) Virus like particle
GB201600380D0 (en) Modified virus
GB201522013D0 (en) Virus
GB201516936D0 (en) Virus